Evaxion A/S
evaxion.aiWhat Do They Do?
Develops AI-designed vaccine candidates for cancer and infectious diseases and offers pharmaceutical companies an AI platform for target discovery, drug design and validation.
20-F for FY2025, filed Mar 5, 2026Evaxion is a pioneering TechBio company based upon our proprietary AI platform, AI-Immunology™, which has been continuously developed and…View ↗
Based upon AI-Immunology™, Evaxion has developed a pipeline of preclinical and clinical R&D-programs, including therapeutic cancer vaccines…View ↗
Evaxion operates in significant markets characterized by high-growth projections. Globally, the market for AI-based drug discovery is…View ↗
Who Are Their Customers?
Pharmaceutical companies work with Evaxion through platform and pipeline partnerships; MSD licensed a vaccine candidate directly from the company.
20-F for FY2025, filed Mar 5, 2026We specialize in target discovery and the early stages of development with a business model based on partnerships around both our platform…View ↗
Evaxion operates in significant markets characterized by high-growth projections. Globally, the market for AI-based drug discovery is…View ↗
In September 2025, the Company out-licensed its vaccine candidate EVX-B3 to MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) as per…View ↗
Do Revenues Turn Into Profits?
No. It lost $7.7M in .
20-F for FY2025, filed Mar 5, 2026
20-F for FY2025, filed Mar 5, 2026
−$7.7MView ↗
How Are They Changing?
A unified AI platform
The earlier report described separate AI tools for cancer, bacterial and viral targets; the latest presents AI-Immunology as a platform with broad applicability across diseases.
20-F for FY2022, filed Apr 28, 2023 20-F for FY2025, filed Mar 5, 2026Our AI Platforms and Product Development PipelineView ↗
PIONEER is our AI platform for the discovery of patient-specific cancer targets which we use to develop truly personalized cancer…View ↗
EDEN is our AI platform for the discovery of bacterial disease targets. EDEN has been designed to identify novel infectious disease targets…View ↗
RAVEN is our AI platform for the discovery of viral disease targets. RAVEN combines the essential AI tools from our PIONEER platform with…View ↗
Broader partnership scope
The earlier report described partnering immunotherapies after proof of concept; the latest describes partnerships around both its AI platform and vaccine pipeline, with work from target discovery through early clinical development.
20-F for FY2022, filed Apr 28, 2023 20-F for FY2025, filed Mar 5, 2026We aim to capture the value from the predictive power of our proprietary AI platforms and their ability to identify novel targets for drug…View ↗
Autoimmune disease planned
The latest report names autoimmune disease as a planned expansion, while the earlier report described work in cancer immunotherapies and infectious diseases.
20-F for FY2022, filed Apr 28, 2023 20-F for FY2025, filed Mar 5, 2026We aim to capture the value from the predictive power of our proprietary AI platforms and their ability to identify novel targets for drug…View ↗
Evaxion is a pioneering TechBio company based upon our proprietary AI platform, AI-Immunology™, which has been continuously developed and…View ↗
Loading...
